Philogen Collaborates with Johnson&Johnson (J&J), Novartis and Celgene

 Philogen Collaborates with Johnson&Johnson (J&J), Novartis and Celgene

Philogen Collaborates with Johnson&Johnson (J&J), Novartis and Celgene

Shots:

  • Philogen collaborates with J&J to discover & develop therapies utilizing Philochem’s technology (a Swizz subsidiary of Philogen) for serious conditions
  • Philogen signs a development and commercialization agreement with Celgene for novel immunomodulatory therapies
  • Philogen collaborates with Novartis for the research and development of immunomodulatory candidates. In 2017 & 2016, Philogen also collaborated with Boehringer Ingelheim (BI) and Pfizer to develop and commercialize DNA-encoded therapies & ADCs for multiple therapy areas respectively

Click Here  read full press release/ article | Ref: Philogen | Image: Twitter

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post